comparemela.com

Latest Breaking News On - Cx alternative investment fund - Page 1 : comparemela.com

CX Partners-backed Veeda Clinical Research gets Sebi nod for its Rs 832 crore IPO

CX Partners-backed Veeda Clinical Research gets Sebi nod for its Rs 832 crore IPO
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

Latest News | Medanta Brand Owner Global Health, Veeda Clinical Get Sebi s Go-ahead to Float IPOs

Get latest articles and stories on Latest News at LatestLY. Global Health Ltd, which operates and manages hospitals under the Medanta brand, and clinical research organisation Veeda Clinical Research has received markets regulator Sebi s go-ahead to raise funds through an initial public offering (IPO). Latest News | Medanta Brand Owner Global Health, Veeda Clinical Get Sebi s Go-ahead to Float IPOs.

CX Partners-backed Veeda Clinical Research gets Sebi nod for its Rs 832 crore IPO

CX Partners-backed Veeda Clinical Research gets Sebi nod for its Rs 832 crore IPO
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

CX Alternative-backed clinical research firm Veeda to raise over $111m via IPO

CX Alternative-backed clinical research firm Veeda to raise over $111m via IPO
dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.

CX Partners-backed Veeda Clinical Research files for IPO to raise 831 cr

CX Partners-backed Veeda Clinical Research files for IPO to raise 831 cr
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.